Sex-Based Analysis of Workflow and Outcomes in Acute Ischemic Stroke Patients Treated With Alteplase Versus Tenecteplase
Diana J. Kim,Nishita Singh,Luciana Catanese,Amy Y.X. Yu,Andrew M. Demchuk,Mar I. Lloret-Villas,Yan Deschaintre,Shelagh B. Coutts,Houman Khosravani,Ramana Appireddy,Francois Moreau,Gord Gubitz,Aleksander Tkach,Dar Dowlatshahi,George Medvedev,Jennifer Mandzia,Aleksandra Pikula,Jai Shankar,Heather Williams,Herbert Manosalva,Muzaffar Siddiqui,Atif Zafar,Oje Imoukhuede,Gary Hunter,Stephen Phillips,Michael D. Hill,Alexandre Y. Poppe,Ayoola Ademola,Michel Shamy,Fouzi Bala,Tolulope T. Sajobi,Richard H. Swartz,Mohammed A. Almekhlafi,Bijoy K. Menon,Thalia S. Field
DOI: https://doi.org/10.1161/strokeaha.123.045320
IF: 10.17
2024-01-06
Stroke
Abstract:Stroke, Ahead of Print. BACKGROUND:Understanding sex differences in stroke care is important in reducing potential disparities. Our objective was to explore sex differences in workflow efficiency, treatment efficacy, and safety in the AcT trial (Alteplase Compared to Tenecteplase).METHODS:AcT was a multicenter, registry-linked randomized noninferiority trial comparing tenecteplase (0.25 mg/kg) with alteplase (0.9 mg/kg) in acute ischemic stroke within 4.5 hours of onset. In this post hoc analysis, baseline characteristics, workflow times, successful reperfusion (extended Thrombolysis in Cerebral Infarction score ≥2b), symptomatic intracerebral hemorrhage, 90-day functional independence (modified Rankin Scale score, 0–1), and 90-day mortality were compared by sex. Mixed-effects regression analysis was used adjusting for age, stroke severity, and occlusion site for outcomes.RESULTS:Of 1577 patients treated with intravenous thrombolysis (2019–2022), 755 (47.9%) were women. Women were older (median, 77 [68–86] years in women versus 70 [59–79] years in men) and had a higher proportion of severe strokes (National Institutes of Health Stroke Scale score >15; 32.4% versus 24.9%) and large vessel occlusions (28.7% versus 21.5%) compared with men. All workflow times were comparable between sexes. Women were less likely to achieve functional independence (31.7% versus 39.8%; unadjusted relative risk, 0.80 [95% CI, 0.70–0.91]) and had higher mortality (17.7% versus 13.3%; unadjusted relative risk, 1.33 [95% CI, 1.06–1.69]). Adjusted analysis showed no difference in outcomes between sexes.CONCLUSIONS:Differences in prognostic factors of age, stroke severity, and occlusion site largely accounted for higher functional dependence and mortality in women. No sex disparities were apparent in workflow quality indicators. Given the integration of the AcT trial into clinical practice, these results provide reassurance that no major sex biases are apparent in acute stroke management throughout participating Canadian centers.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT03889249.
peripheral vascular disease,clinical neurology